Clarus Therapeutics Inc., of Northbrook, Ill., said that Lipocine Inc., of Salt Lake City, has confirmed that it will not seek preliminary injunctive relief against the company in a lawsuit that asserts its product Jatenzo infringes certain Lipocine patents, even in the event that the product, an oral testosterone undecanoate capsule for the treatment of appropriate men with testosterone deficiency, is launched. A trial date in the dispute has been set for August 24, 2020, in the U.S. District Court for the District of Delaware.